Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 10/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818760 | 0.99 | PLK1 (0.49) | PLK1KDM4EHSD17B10SERPINE1ALB | |
| SCHEMBL6834113 | 0.96 | KDM4E (0.46) | PLK1KDM4EHSD17B10SERPINE1ALB | |
| SCHEMBL6819558 | 0.89 | POLB (0.51) | PLK1KDM4EALBAKR1C4AKR1C3 | |
| SCHEMBL6833223 | 0.88 | POLB (0.52) | PLK1KDM4EALBAKR1C4AKR1C3 | |
| SCHEMBL6835722 | 0.87 | PLK1 (0.57) | PLK1KDM4ESERPINE1ALBPLK3 | |
| SCHEMBL6833718 | 0.87 | ALB (0.58) | PLK1ALBAKR1C2AKR1C1PLK3 | |
| SCHEMBL6822748 | 0.87 | ALB (0.58) | PLK1ALBAKR1C2AKR1C1PLK3 | |
| SCHEMBL6814498 | 0.87 | ALB (0.58) | PLK1ALBAKR1C2AKR1C1PLK3 | |
| SCHEMBL6819812 | 0.87 | ALB (0.58) | PLK1ALBAKR1C2AKR1C1PLK3 | |
| SCHEMBL6818796 | 0.85 | ALB (0.59) | PLK1KDM4EALBAKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | PLK1 4270/4885KDM4E 1240/4885HSD17B10 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.